Debt to Equity
since 2018
Calculation
Moderna Inc., debt to equity, long-term trends, calculation
| Debt to equity | = | Financing lease liabilities1 | ÷ | Stockholders’ equity1 | |
|---|---|---|---|---|---|
| Dec 31, 2023 | 0.04 | = | 575) | ÷ | 13,854) |
| Dec 31, 2022 | 0.06 | = | 1,073) | ÷ | 19,123) |
| Dec 31, 2021 | 0.05 | = | 764) | ÷ | 14,145) |
| Dec 31, 2020 | 0.05 | = | 134) | ÷ | 2,561) |
| Dec 31, 2019 | 0.03 | = | 39) | ÷ | 1,175) |
| Dec 31, 2018 | 0.03 | = | 43) | ÷ | 1,530) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$ in millions
Comparison to Competitors
Moderna Inc., debt to equity, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | 0.04 | 5.73 | 10.37 | 1.35 | 0.34 | 2.34 | 1.09 | 0.43 | 0.93 | 0.81 | 0.10 | 0.75 |
| Dec 31, 2022 | 0.06 | 3.67 | 10.64 | 1.27 | 0.39 | 1.52 | 1.19 | 0.52 | 0.67 | 0.37 | 0.12 | 0.78 |
| Dec 31, 2021 | 0.05 | 4.98 | 4.97 | 1.24 | 0.49 | 1.88 | 1.27 | 0.46 | 0.87 | 0.50 | 0.14 | 0.85 |
| Dec 31, 2020 | 0.05 | 6.58 | 3.51 | 1.34 | 0.53 | 2.94 | 1.73 | 0.56 | 1.26 | 0.63 | 0.24 | 0.63 |
| Dec 31, 2019 | 0.03 | — | 3.09 | 0.91 | 0.72 | 5.88 | 1.09 | 0.47 | 1.02 | 0.83 | 0.06 | 0.60 |
| Dec 31, 2018 | 0.03 | — | 2.71 | 0.52 | 0.35 | 1.30 | 1.28 | 0.51 | 0.94 | 0.66 | 0.08 | 0.69 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., debt to equity, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2023 | 0.04 | 0.98 |
| Dec 31, 2022 | 0.06 | 0.79 |
| Dec 31, 2021 | 0.05 | 0.92 |
| Dec 31, 2020 | 0.05 | 1.14 |
| Dec 31, 2019 | 0.03 | 1.10 |
| Dec 31, 2018 | 0.03 | 0.94 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., debt to equity, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Dec 31, 2023 | 0.04 | 0.81 |
| Dec 31, 2022 | 0.06 | 0.72 |
| Dec 31, 2021 | 0.05 | 0.78 |
| Dec 31, 2020 | 0.05 | 0.90 |
| Dec 31, 2019 | 0.03 | 0.91 |
| Dec 31, 2018 | 0.03 | 0.87 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).